Journal of Hematology & Oncology

Papers
(The median citation count of Journal of Hematology & Oncology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
ArticleCitations
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity713
Targeting the Wnt/β-catenin signaling pathway in cancer678
Nanomaterials for cancer therapy: current progress and perspectives530
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19490
EZH2: a novel target for cancer treatment475
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer390
NK cell-based cancer immunotherapy: from basic biology to clinical development334
Next generation of immune checkpoint inhibitors and beyond316
Regulation of PD-L1 expression in the tumor microenvironment313
Roles of METTL3 in cancer: mechanisms and therapeutic targeting287
Challenges and advances in clinical applications of mesenchymal stromal cells275
cGAS-STING, an important pathway in cancer immunotherapy274
Cancer vaccines as promising immuno-therapeutics: platforms and current progress257
RNA sequencing: new technologies and applications in cancer research250
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)243
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy240
Combination strategies to maximize the benefits of cancer immunotherapy231
Isolation and characterization of exosomes for cancer research225
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis223
Dendritic cell biology and its role in tumor immunotherapy217
Immunosenescence: a key player in cancer development214
Targeting mutant p53 for cancer therapy: direct and indirect strategies213
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling210
Targeting hypoxic tumor microenvironment in pancreatic cancer209
Novel therapies emerging in oncology to target the TGF-β pathway208
Neutrophils in cancer carcinogenesis and metastasis207
Liquid biopsy: current technology and clinical applications206
Applications of single-cell sequencing in cancer research: progress and perspectives200
Recent advances in CAR-T cell engineering198
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells195
Recent advances in therapeutic strategies for triple-negative breast cancer195
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions188
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research187
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response187
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)182
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy176
Oncolytic viruses for cancer immunotherapy172
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma166
RNA-binding proteins in tumor progression163
Targeting CD47 for cancer immunotherapy163
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation162
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study156
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019155
Targeting MCL-1 in cancer: current status and perspectives153
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway152
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets151
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy149
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies146
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti144
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer143
MEK inhibitors for the treatment of non-small cell lung cancer141
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy140
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019139
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target136
Antibody–drug conjugates in solid tumors: a look into novel targets135
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends134
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update134
HMGB1 in inflammation and cancer132
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1131
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape130
Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis128
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment128
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy128
Modeling neoplastic disease with spheroids and organoids127
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies124
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin123
Exploring immunotherapy in colorectal cancer121
The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017120
XPO1-dependent nuclear export as a target for cancer therapy120
Role of lysosomes in physiological activities, diseases, and therapy117
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy116
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential114
Mesenchymal stem/stromal cells in cancer therapy114
The management of metastatic GIST: current standard and investigational therapeutics113
Targeting autophagy to overcome drug resistance: further developments112
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies111
BCMA-targeted immunotherapy for multiple myeloma110
Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy110
tRNA-derived RNA fragments in cancer: current status and future perspectives108
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies107
Emerging agents and regimens for AML106
The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands105
Targeting Akt in cancer for precision therapy105
Emerging strategies to target RAS signaling in human cancer therapy100
The potential role of N7-methylguanosine (m7G) in cancer99
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation99
Targeting EphA2 in cancer98
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions98
The long and short non-coding RNAs modulating EZH2 signaling in cancer97
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma97
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward96
Gastric cancer treatment: recent progress and future perspectives95
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts95
Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer94
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents94
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma93
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia92
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma89
HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk87
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment86
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties86
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC85
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies84
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks83
Role of CD47 in Hematological Malignancies81
Novel therapies are changing treatment paradigms in metastatic prostate cancer79
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA78
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA77
New agents and regimens for diffuse large B cell lymphoma77
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 202176
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers76
Epidemiological trends of tracheal, bronchus, and lung cancer at the global, regional, and national levels: a population-based study75
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer74
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients74
Prostate cancer and PARP inhibitors: progress and challenges73
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma72
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia72
Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer71
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications71
Crosstalks between inflammasome and autophagy in cancer71
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges71
FGFR-TKI resistance in cancer: current status and perspectives71
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation71
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors71
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials71
Targeting immune checkpoints in hematological malignancies69
CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma68
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential68
STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib67
Born to survive: how cancer cells resist CAR T cell therapy67
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas66
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies66
Advances in the diagnosis and treatment of sickle cell disease64
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors64
SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism63
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma63
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management63
Third-line therapy for chronic myeloid leukemia: current status and future directions62
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study62
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance62
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)62
N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer61
Principles and innovative technologies for decrypting noncoding RNAs: from discovery and functional prediction to clinical application61
Thrombocytopenia and thrombosis in hospitalized patients with COVID-1960
Emerging strategies to overcome resistance to third-generation EGFR inhibitors60
Tumor organoids: applications in cancer modeling and potentials in precision medicine60
Natural killer cell-based immunotherapy for acute myeloid leukemia60
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors60
Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity59
Targeting macrophages in hematological malignancies: recent advances and future directions59
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses58
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies57
The emerging role of KDM5A in human cancer57
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer56
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes55
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies55
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target55
CAR-T cells and BiTEs in solid tumors: challenges and perspectives55
Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017: an up-to-date overview and comparison with those in Japan and South Korea55
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma55
Emerging agents and regimens for multiple myeloma54
Payload diversification: a key step in the development of antibody–drug conjugates53
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR53
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party o53
Therapeutic strategies in RET gene rearranged non-small cell lung cancer52
Molecular pathogenesis of the myeloproliferative neoplasms52
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors52
Beyond thrombosis: the impact of tissue factor signaling in cancer52
Prognostic and predictive biomarker developments in multiple myeloma52
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma51
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN151
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer51
Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy51
STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer50
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies50
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy50
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials49
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy49
The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia49
Circadian rhythms and cancers: the intrinsic links and therapeutic potentials48
The functions and clinical significance of circRNAs in hematological malignancies48
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma48
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy48
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies47
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities47
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation47
How we treat NK/T-cell lymphomas47
Th17 cells inhibit CD8+ T cell migration by systematically downregulating CXCR3 expression via IL-17A/STAT3 in advanced-stage colorectal cancer patients47
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial47
Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data47
A single-cell survey of cellular hierarchy in acute myeloid leukemia47
Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals47
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia46
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matche46
Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism46
CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer46
Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF/miR-192-5p/CYR61/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment46
Protein degradation technology: a strategic paradigm shift in drug discovery46
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies45
Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma45
Integrins regulate stemness in solid tumor: an emerging therapeutic target45
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients44
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity44
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)44
Interplay between endoplasmic reticulum stress and non-coding RNAs in cancer44
Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers44
RETRACTED ARTICLE: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA43
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma43
Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma42
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy42
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies42
Molecular and cellular mechanisms of aging in hematopoietic stem cells and their niches42
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia42
Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway41
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia41
Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers41
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes40
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress40
Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor microenvironment40
Momelotinib: an emerging treatment for myelofibrosis patients with anemia40
Functions, mechanisms, and therapeutic implications of METTL14 in human cancer40
Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN40
Drugging KRAS: current perspectives and state-of-art review39
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia39
High-throughput approaches for precision medicine in high-grade serous ovarian cancer39
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia38
The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer38
Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled t38
Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma38
Long non-coding RNAs in brain tumors: roles and potential as therapeutic targets38
Recent advances in targeted therapies in acute myeloid leukemia38
Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study38
Hemophagocytic lymphohistiocytosis after COVID-19 vaccination38
Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis37
Targeting oncogenic Notch signaling with SERCA inhibitors37
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer37
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies36
Current understanding of extrachromosomal circular DNA in cancer pathogenesis and therapeutic resistance36
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer36
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia35
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application35
Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications35
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia35
Current and future treatment strategies in chronic lymphocytic leukemia35
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting35
m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis35
Novel targeted therapies of T cell lymphomas35
The biogenesis and biological function of PIWI-interacting RNA in cancer34
Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion34
A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes33
0.036720037460327